FDA’s “Complete Response” Letters May Not Be Complete Enough For Firms
Executive Summary
FDA's "complete response" final regulations finally do away with negative connotations of the "not approvable" label used by the agency since the 1990s, but they will not provide more certainty for sponsors about how to answer FDA's problems with an application
You may also be interested in...
FDA’s Risk/Benefit Decisions Will Be Quantified With Metric From Contractor
A recent request for proposals may signal a shift in FDA's approach to risk/benefit analysis and views on outcome measures, a move some see as bringing more transparency while also shielding the agency from criticism
For NME Approvals, 2008 Looks A Lot Like 2007 At Mid-Year; Will Changes At FDA Turn The Tide?
So far, the approval trends for new molecular entities and novel biologics in the first half of 2008 suggest that this year's final tally may look very similar to last year's record-low approval total
FDA’s Risk/Benefit Decisions Will Be Quantified With Metric From Contractor
A recent request for proposals may signal a shift in FDA's approach to risk/benefit analysis and views on outcome measures, a move some see as bringing more transparency while also shielding the agency from criticism